Clinical features and outcomes of unresectable locally advanced lung adenocarcinoma with uncommon EGFR mutations: a retrospective multi-center Chinese study.

ABSTRACT:

Background

Uncommon epidermal growth factor receptor (EGFR) gene mutant locally advanced non-small cell lung cancer (NSCLC) has been poorly documented in the literature. Our study aimed to investigate the clinical features and outcomes associated with these mutations.

Methods

A multi-center retrospective study was conducted to review 511 patients with EGFR mutant unresectable stage III lung adenocarcinoma, treated between 2012 and 2018 across 12 Chinese institutions. The patients were categorized into three groups based on their primary treatment: chemoradiotherapy (CRT), EGFR-TKIs (tyrosine kinase inhibitors), and radiotherapy (RT) combined with EGFR-TKIs.

Results

Among the 511 patients, 49 (9.6%) had uncommon EGFR mutations. Of the

SUBMITTER: Xu K 

PROVIDER: S-EPMC11826267 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature